688428.SH上海证券交易所 · 科创板 STAR
Innocare 诺诚健华
Chemical Pharmaceuticals 化学制药
¥29.86−¥3.54 · −10.60%
Open 开盘
¥33.14
High 最高
¥35.00
Low 最低
¥29.80
Prev Close 昨收
¥33.40
Volume 成交量
3,031.8万股
Turnover 成交额
¥9.51亿
Mkt Cap 总市值
¥528亿
P/E 市盈率
57.5×
Recent Activity 近期动态All Filings 全部公告 →
19 significant filings since 29 May 2026: 15 on equity incentive, 2 on major holder selling and 1 on major contract or bid won, and 1 other kind. The latest, on 24 Sep 2026: 诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告.
自 29 May 2026 起有 19 份重大公告：equity incentive 15 份、major holder selling 2 份、major contract or bid won 1 份，另有 1 类。最新一份（24 Sep 2026）：诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥34.00 · Low 最低 ¥28.14 · −10.60% on the previous close of ¥33.4029.0030.0031.0032.0033.00
Volume 成交量
281.0万
18 Sep21 Sep22 Sep23 Sep24 Sep
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥528亿 | ¥63亿 | 7th highest of 158 · 158 家中第 7 高 | |
| Trailing P/E 市盈率 | 57.5x | 38.6x | 43rd highest of 112 · 112 家中第 43 高 | |
| P/B 市净率 | 6.9x | 2.5x | 24th highest of 157 · 157 家中第 24 高 | |
| Revenue Growth 营收增速 | 55.5% | 1.6% | 9th highest of 156 · 156 家中第 9 高 | |
| Profit Growth 净利增速 | 918.7% | 1.9% | 6th highest of 158 · 158 家中第 6 高 | |
| Gross Margin 毛利率 | 89.5% | 50.2% | 8th highest of 155 · 155 家中第 8 高 | |
| Net Margin 净利率 | 21.1% | 9.8% | 25th highest of 157 · 157 家中第 25 高 | |
| Return on Equity 净资产收益率 | 3.2% | 3.1% | 73rd highest of 157 · 157 家中第 73 高 | |
| Debt to Assets 资产负债率 | 31.5% | 28.0% | 75th highest of 158 · 158 家中第 75 高 | |
| Grade Score 评级得分 | 68 | 51 | 22nd highest of 157 · 157 家中第 22 高 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,979亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,977亿 | 38.5x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥699亿 | 73.7x | 14.3x | 54.7% | 27.5% | 18.3% | B |
| CSPC Innovation Pharmaceutical 石药创新 | ¥620亿 | 60.6x | 15.8x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥618亿 | 33.8x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Fosun Pharma 复星医药 | ¥610亿 | 18.0x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| Innocare 诺诚健华 | ¥528亿 | 57.5x | 6.9x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥469亿 | 17.5x | 5.5x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥457亿 | 13.2x | 1.8x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥337亿 | 50.0x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥293亿 | 34.5x | 4.5x | -11.4% | 10.8% | 8.1% | D |
| Zelgen 泽璟制药 | ¥288亿 | 52.5x | 16.8x | 220.9% | 53.1% | 45.7% | B |
| Dizal Pharmaceutical 迪哲医药 | ¥263亿 | — | 23.2x | 47.2% | -40.8% | -17.2% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。